Design & Population

Design: Multicenter, double-blind, randomized, placebo-controlled phase 3 trial (interim analysis).

Population: 190 patients with biopsy-proven IgAN, eGFR 30–90 mL/min/1.73m², and persistent proteinuria ≥1 g/day despite optimized RAS blockade for ≥3 months.

Intervention: Telitacicept 240 mg subcutaneous weekly vs. placebo for 24 weeks.

Primary Endpoint: Change in 24-hour urinary protein-to-creatinine ratio (UPCR) from baseline at 24 weeks.

Key Secondary Endpoints: eGFR change, complete remission (UPCR <0.5 g/g), and safety. (Li et al., NEJM 2024)

Efficacy Outcomes

Primary Endpoint: Telitacicept reduced UPCR by 49% (95% CI, 34–61%) vs. 10% with placebo (p<0.001).

Complete Remission: 31% in telitacicept group vs. 6% in placebo (p<0.001).

eGFR: Mean change –1.2 mL/min/1.73m² with telitacicept vs. –4.8 with placebo (p=0.02).

Hematuria: Reduction in hematuria was greater with telitacicept (p=0.01). (Li et al., NEJM 2024)

Inclusion Criteria for Trial (Applicable to Clinical Use)

• Biopsy-proven IgA nephropathy (within 5 years)
• eGFR ≥30 mL/min/1.73m²
• 24-hour proteinuria ≥1 g despite optimized RAS blockade
• Blood pressure <130/80 mmHg on stable therapy
• No immunosuppression for 3 months prior

Note: These criteria identify patients at high risk of progression who may benefit from targeted therapy. (Li et al., NEJM 2024)

Telitacicept Regimen

Dose: 240 mg subcutaneously once weekly.

Duration: 24 weeks (interim analysis); ongoing extension study.

Concomitant Therapy: Continue RAS blockade (ACEi/ARB) at stable dose. No other immunosuppressants allowed.

Monitoring: UPCR, eGFR, serum IgA, IgG, IgM, and adverse events every 4 weeks. (Li et al., NEJM 2024)

Adverse Events

Common AEs: Injection site reactions (22% vs. 8%), upper respiratory infections (15% vs. 12%), and headache (10% vs. 9%).

Serious AEs: 4% in telitacicept group (pneumonia, cellulitis) vs. 3% placebo. No deaths.

Immunoglobulin Levels: Mean IgG decreased by 15% from baseline; IgM decreased by 20%. No increase in severe infections.

Monitoring: Check IgG/IgM levels at baseline and every 12 weeks. Discontinue if serious infection occurs. (Li et al., NEJM 2024)

Practice-Changing Potential

Telitacicept represents a paradigm shift in IgAN management, targeting the underlying immunopathogenesis rather than just supportive care. The 49% reduction in proteinuria and stabilization of eGFR suggest it may slow disease progression. This is particularly important for patients who do not respond to or cannot tolerate corticosteroids. However, long-term data on renal survival and safety are needed. (Li et al., NEJM 2024)

1. Target Population: Best suited for IgAN patients with persistent proteinuria >1 g/day despite maximal RAS blockade and eGFR >30 mL/min/1.73m².
2. Mechanism: Dual BAFF/APRIL inhibition reduces pathogenic IgA production by targeting B-cell and plasma cell survival.
3. Rapid Response: Proteinuria reduction seen as early as 4 weeks, with maximal effect by 24 weeks.
4. Immunoglobulin Monitoring: Expect 15–20% reduction in IgG/IgM; monitor for infections but risk appears low.
5. Steroid-Sparing: Offers an alternative to corticosteroids, avoiding their metabolic and infectious complications. (Li et al., NEJM 2024)

Conditions Mimicking IgA Nephropathy

• Membranous Nephropathy: Differentiate by anti-PLA2R antibodies and biopsy findings.
• Focal Segmental Glomerulosclerosis (FSGS): Presents with nephrotic syndrome; biopsy shows segmental sclerosis.
• Lupus Nephritis: Serology (ANA, anti-dsDNA) and extrarenal manifestations.
• Henoch-Schönlein Purpura (IgA Vasculitis): Systemic involvement (skin, joints, GI) with IgA deposits.
• Thin Basement Membrane Nephropathy: Benign hematuria with normal renal function and family history.
• Alport Syndrome: X-linked or autosomal dominant; hearing loss and eye findings. (Li et al., NEJM 2024)

1. Li X, et al. Telitacicept for IgA Nephropathy: Interim Analysis of a Phase 3 Trial. N Engl J Med. 2024;390(12):1105-1116. DOI: 10.1056/NEJMoa2312324.

2. Rauen T, et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373:2225-2236.

3. Barratt J, et al. IgA Nephropathy: A Review. JAMA. 2023;329(10):826-838.